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Abstract  28 
In this study hot-melt co-extrusion is used as processing technique to manufacture a fixed-29 
dose combination product providing enteric protection to naproxen incorporated in the core 30 
and immediate release to esomeprazole magnesium embedded in the coat. The plasticizing 31 
effect of naproxen and triethyl citrate (TEC) was tested on the enteric polymers investigated 32 
(Eudragit® L100-55, HPMC-AS-LF and HPMCP-HP-50). Core matrix formulations containing 33 
HPMC-AS-LF, TEC and a naproxen load of 15, 30 and 50% were processed and 34 
characterized. The in vitro naproxen release in 0.1N HCl was prevented for 2h for all 35 
formulations. The physicochemical state of the drug in the extrudates was determined and a 36 
stability study was performed. Intermolecular interactions between naproxen and polymer were 37 
identified using attenuated total reflection Fourier-transform infrared (ATR FT-IR) 38 
spectroscopy. When esomeprazole magnesium was formulated in a polyethylene oxide 39 
100K:polyethylene glycol 4K (1:1) matrix, separated from the naproxen-containing layer, the 40 
formulation could be easily processed and complete in vitro drug release was observed after 41 
45min. When co-extruding the core/coat dosage form it was observed that a third layer of 42 
polymer, separating the naproxen loaded enteric formulation in the core from the coat, is 43 
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1. INTRODUCTION 56 
Hot-melt co-extrusion is defined as the simultaneous hot-melt extrusion of two or more 57 
materials creating a multi-layered extrudate (Vynckier et al., 2014a). This continuous 58 
manufacturing technique still has to break through in pharmaceutical production, although 59 
several literature reports are already available on the use of co-extrusion for oral drug delivery. 60 
Quintavalle et al. (Quintavalle et al., 2007, 2008) were the first to produce cylindrical co-61 
extrudates with controlled drug release via hot-melt extrusion, using polyethylene glycol as 62 
hydrophilic matrix and stearic acid or microcrystalline wax as hydrophobic matrix. Co-extruded 63 
mini-matrices have recently been formulated using core/coat technology with drugs 64 
incorporated in different polymer matrices in order to steer the release of different drugs 65 
(Dierickx et al., 2012; Vynckier et al., 2014b) or to provide a dual release of a single drug 66 
(Dierickx et al., 2013). Although co-extrusion offers the potential to formulate fixed-dose 67 
combination products containing two chemically incompatible drugs in separate layers, this 68 
application has not yet been reported. 69 
The present study investigated if hot-melt co-extrusion allowed to manufacture a fixed-70 
dose combination product providing enteric protection to the active pharmaceutical ingredient 71 
(API) incorporated in the core and immediate release to the API embedded in the coat. Several 72 
enteric polymers were tested as core matrix former in combination with naproxen. This non-73 
steroidal anti-inflammatory drug (NSAID) was used as a model drug. Since gastro-protective 74 
co-therapy using a proton pump inhibitor is recommended to decrease the incidence of NSAID-75 
related adverse events, esomeprazole magnesium was incorporated in the coat (Cryer et al., 76 
2011; Wang-Smith et al., 2012). Esomeprazole magnesium was formulated in a separate non-77 
enteric polymer layer providing immediate drug release, which is essential to achieve rapid 78 
absorption of esomeprazole (Howden, 2005). For both the core and coat layers different 79 
polymers were tested and their influence on release, physicochemical state characteristics and 80 
stability was monitored. Finally it was evaluated if co-extrusion as an innovative processing 81 
technique of core/coat dosage forms allowed to formulate the two chemically incompatible 82 
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API’s in a bilayer fixed-dose combination and still offered the desired release profile for both 83 
API’s, as obtained by Wang-Smith et al. (2012).  84 
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2. MATERIALS AND METHODS 85 
2.1 Materials 86 
Naproxen (pKa 4.15) (Fagron, Waregem, Belgium) and esomeprazole magnesium 87 
trihydrate (Nifty labs, Hyderabad, India) were chosen as model drugs. Vimovo® (AstraZeneca, 88 
Brussels, Belgium), containing 500 mg enteric-coated naproxen and 20 mg non-enteric coated 89 
esomeprazole Mg, was used as a commercially available reference. The following enteric 90 
polymers were used: methacrylic acid – ethyl acrylate copolymer (1:1) Type A (Eudragit® L100-91 
55, Evonik, Darmstadt, Germany), hydroxypropyl methylcellulose acetate succinate (HPMC-92 
AS-LF, Aqoat® AS-LF, Shin-Etsu, Tokyo, Japan) and hydroxypropyl methylcellulose phthalate 93 
(HPMCP-HP-50, Shin-Etsu, Tokyo, Japan). Triethyl citrate (TEC, Sigma-aldrich, Bornem, 94 
Belgium) and talc (Luzenac® Pharma, Imerys Talc, Gent, Belgium) were used as excipients in 95 
the core formulation. The polymers used in the coat formulation were polyethylene oxide 100K 96 
(PEO 100K, Mw: 100000 g/mol, SentryTM Polyox® WSR N10, Colorcon, Dartford Kent, United 97 
Kingdom), polyvinylpyrrolidone (Kollidon®12 PF, Mw: 2500 g/mol, BASF, Ludwigshafen, 98 
Germany), hydroxypropyl methylcellulose (Methocel® E3, viscosity: 3 mPa.s, Colorcon, 99 
Dartford Kent, United Kingdom), hydroxypropyl cellulose (Klucel® EF, Mw: 80000, Ashland, 100 
Covington, USA) and polyethylene glycol 4K (PEG 4K, Mw: 4000 g/mol, Fagron, Waregem, 101 
Belgium). All other chemicals were of analytical grade. 102 
2.2 Methods 103 
2.2.1 Hot-melt extrusion and co-extrusion 104 
In a first step hot-melt extrusion was performed to select an appropriate polymer matrix for 105 
core and coat separately, using a co-rotating Prism Eurolab 16 mm fully intermeshing twin-106 
screw extruder (ThermoFisher Scientific, Karlsruhe, Germany) connected to a co-extrusion die 107 
having a core and coat insert with a diameter of 4 and 6 mm, respectively (Guill, West Warwick, 108 
USA). For the core formulations the processing temperatures are given in Table 1. The coat 109 
formulation was processed at a temperature of 100 °C in all zones of the extruder and the die. 110 
Premixes of drug, polymer and additives were fed into the extruder using a Brabender 111 
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Flexwall® loss-in-weight powder feeder (Brabender, Duisburg, Germany) at a feed rate of 375 112 
g/h for the coat and 300 g/h for the core material. A screw speed of 120 rpm was used for each 113 
of the extruders. 114 
In a second phase co-extrusion was carried out using two co-rotating Prism Eurolab 16 115 
mm twin-screw extruders (ThermoFisher Scientific, Karlsruhe, Germany), both connected to 116 
the co-extrusion die (Guill, West Warwick, USA). A cylindrical co-extrudate with a core 117 
diameter of 4 mm and a concentric coat with a thickness of 1 mm (total co-extrudate diameter: 118 
6 mm) was manufactured. After cooling to room temperature the cylindrical co-extrudate was 119 
manually cut into cylinders of 10 mm length, which were used for further analysis. 120 
2.2.2 In vitro drug release 121 
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 122 
apparatus 2 (paddles) on an Evolution 6300 dissolution system (Distek, New Brunswick, New 123 
Jersey, USA), coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 124 
Brunswick, New Jersey, USA). The temperature of the dissolution medium was kept at 37 ± 125 
0.5 °C and the rotational speed of the paddles was set to 100 rpm. To characterize the release 126 
of naproxen from the core of the extrudates 750 ml of a 0.1 N solution of HCl was used as the 127 
dissolution medium for the first 2 h. After collecting the 2 h sample, 250 ml Na3PO4.12H2O 0.2 128 
M was added to the dissolution vessel to adjust the pH of the medium to 6.8. Samples (filtered 129 
using Distek 45 µm filters) of 5 ml were withdrawn after 0.5, 1, 1.5 and 2 h in the acid stage 130 
and consequently after 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h and 10 h in the pH 6.8 131 
buffer stage. To assess the esomeprazole magnesium release from drug-loaded coat of the 132 
extrudates a dissolution test in demineralized water was performed for 2 h. For this in vitro 133 
dissolution test samples of 5 ml were withdrawn after 5, 10, 15, 20, 30, 45, 60, 90 and 120 min. 134 
Each experiment was performed in triplicate. 135 
2.2.3 Ultra high performance liquid chromatography (UHPLC) analysis 136 
For the determination of both active compounds in the dissolution samples an ultra high 137 
performance liquid chromatography (UHPLC) analysis was performed using a reversed-phase 138 
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C18 column with a gradient system (10 min) based on aqueous 10 mM ammonium acetate (A) 139 
and acetonitrile (B). The gradient used was: a linear ramp from 0 to 5 min going from 85 % A 140 
+ 15 % B to 50 % A + 50 % B, changing over to 5 % A + 95 % B at 5.1 min, maintained for 1.8 141 
min and afterwards changing over to chromatographic start conditions 85 % A + 15 % B from 142 
6.9 min to 7 min, followed by an equilibration of 3 min preceding the next injection. An Acquity 143 
CSH C18 column (1.7 µm particle size, 2.1 x 100 mm) (Waters, Brussels, Belgium) was used 144 
in an oven set at 40 °C. The flow rate was set at 0.35 ml/min, injection volume was 0.3 µl. A 145 
photo-diode array detector (Acquity, Waters, Brussels, Belgium) was used. For the 146 
quantification of esomeprazole a detection wavelength of 290 nm was used, whereas for 147 
naproxen the detection wavelength was set at 260 nm. An appropriate calibration curve was 148 
applied for quantification of esomeprazole and naproxen, respectively.  149 
For the quantification and purity determination of esomeprazole in the solid dosage forms 150 
a verified UHPLC method was developed, using an Acquity CSH C18 column (1.7 µm particle 151 
size, 2.1 x 100 mm) (Waters, Brussels, Belgium) in an oven set at 40 °C, with a gradient system 152 
(30 min) based on the same two-component mobile phase system: aqueous 10 mM 153 
ammonium acetate (A) and acetonitrile (B). The gradient used here was: a linear ramp from 2 154 
to 20 min going from 90 % A + 10 % B to 5 % A + 95 % B, holding this condition for 5 min and 155 
afterwards changing over to chromatographic start conditions 90 % A + 10 % B from 25 to 25.1 156 
min, maintaining this condition for 4.9 min as an equilibration step preceding a next injection. 157 
The flow rate was set at 0.35 ml/min, an injection volume of 1.2 µl was used. For the 158 
quantification of esomeprazole a photo-diode array detector (Acquity, Waters, Brussels, 159 
Belgium), with a detection wavelength set at 301 nm, was used. Sample preparation was 160 
performed by stirring the extrudates in a 10 ml flask filled with demineralized water : acetonitrile 161 
in a 1 : 1 ratio. An appropriate calibration curve was applied for quantification of esomeprazole.  162 
The UHPLC system consisted of an isocratic solvent pump, an automatic autosampler and 163 
a column oven (Acquity, Waters, Brussels, Belgium). Peak integration and data acquisition 164 
was performed using the software package Empower® (Waters, Brussels, Belgium).   165 
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2.2.4 Modulated differential scanning calorimetry (MDSC) 166 
The crystallinity of naproxen in the enteric core matrix and the thermal behavior of pure 167 
compounds, physical mixtures and corresponding extrudates were studied using a differential 168 
scanning calorimeter Q2000 V24.8 equipped with a refrigerated cooling system (TA 169 
Instruments, Leatherhead, UK). Nitrogen was used as purge gas through the DSC cell (50 170 
ml/min) and the RCS unit (300 ml/min). Samples (± 8 mg) were run in hermetically closed 171 
Tzero pans with perforated lid, supplied by TA Instruments, with an underlying heating rate of 172 
2 °C/min. The modulation period and amplitude were set at 60 s and 0.318 °C, respectively. 173 
After a first heating cycle to 175 °C, samples were cooled to -30 °C using a linear cooling rate 174 
of 10 °C/min. Finally, a second modulated heating cycle was applied. Mass of sample pan and 175 
empty reference pan were taken into account. Temperature and enthalpy calibration were 176 
performed using an indium standard, whereas calibration of the heat capacity was performed 177 
using a sapphire standard. MDSC data were analyzed using the TA Instruments Universal 178 
Analysis 2000 V4.7A software. Melting enthalpies and glass transition temperatures were 179 
determined in the total heat flow signal and reversing heat flow signal, respectively. Reported 180 
glass transition temperatures of the physical mixtures were determined in the second heating 181 
cycle to ensure maximal interaction between the compounds and to simulate a thermal history 182 
comparable to the extrudates when analyzed during the first heating cycle in MDSC. The 183 
degree of crystallinity was calculated comparing the melting enthalpy of the naproxen melting 184 
peak in the analyzed sample to that of pure naproxen (147.2 J/g). 185 
2.2.5 X-ray diffraction 186 
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 187 
mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 188 
diffractometer with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a voltage 189 
of 40 mV in the angular range (2θ) varying from 4 to 60 ° using a step scan mode with a step 190 
size of 0.02 ° and a measuring time of 1 s/step. 191 
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2.2.6 Attenuated total reflection Fourier-transform infrared analysis 192 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 193 
performed on the pure substances, physical mixtures and extrudates to identify molecular 194 
interactions formed between naproxen and the enteric polymers during extrusion. Spectra 195 
were recorded in absorbance mode using a Nicolet iS5 ATR FT-IR spectrometer 196 
(ThermoFisher Scientific, Karlsruhe, Germany). A diamond ATR crystal was pressed against 197 
the samples in order to obtain the ATR FT-IR spectra in the 4000 – 550 cm-1 range, with a 198 
resolution of 4 cm-1, averaged over 32 scans. 199 
2.2.7 Stability study 200 
Clear core extrudates formulated with different polymer matrices and 30 % naproxen 201 
(Table 1), and core extrudates containing 50 % naproxen and 50 % HPMC-AS-LF were 202 
manufactured to perform a stability study. Immediately after extrusion, the formulations were 203 
filled in an amber glass container and stored in closed condition at 25 °C / 60 %RH and in open 204 
and closed condition at 40 °C / 75 %RH. To investigate the influence of storage MDSC, XRD, 205 
and in vitro drug release tests were performed on the extrudates immediately after 206 
manufacturing (T0), after 1 week (T1w), 2 weeks (T2w), 1 month (T1m) or 6 weeks (T6w), 3 207 
months (T3m) and 6 months (T6m) storage.  208 
  209 
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3. RESULTS AND DISCUSSION 210 
In order to formulate a core/coat fixed-dose combination product via co-extrusion both 211 
layers were first independently developed. Afterwards the compatibility of the core and coat 212 
matrices was checked. Finally it was evaluated if the final drug-loaded formulations were 213 
compatible and if a fixed-dose combination product with the desired release characteristics 214 
could be manufactured via co-extrusion.  215 
3.1. Core formulation  216 
To develop a core matrix formulation providing enteric protection for naproxen, using hot-217 
melt extrusion (HME) as production technology, three enteric polymers were compared: 218 
methacrylic acid - ethylacrylate copolymer (Eudragit® L100-55), hypromellose acetate 219 
succinate (HPMC-AS-LF) and hypromellose phthalate (HPMCP-HP-50). Hot-melt extrusion of 220 
these polymers in combination with 15% naproxen required a plasticizer as without plasticizer 221 
the torque values during extrusion were too high. Although naproxen (with a melting point at 222 
156.1 °C and a glass transition temperature (Tg) of 6.2 °C) (Alleso et al., 2009) had a 223 
concentration-dependent plasticizing effect on these polymers (Table 2), the effect of this 224 
polymer/drug interaction on the process temperature and/or torque during extrusion cannot be 225 
exploited to its full extent as the plasticizing effect was only evident during the second heating 226 
cycle of the MDSC analysis of a physical mixture. Hence, these drug/polymer interactions were 227 
only established after intense intermolecular contact following the 1st heating phase of the 228 
MDSC experiment.  229 
TEC was an efficient plasticizer for Eudragit® L100-55, reducing its Tg from 117.7 °C to 230 
108.5 and 90.2 °C after the 1st and 2nd heating cycle, respectively, at a concentration of 10 % 231 
TEC. For this formulation a screw speed of 120 rpm and a higher processing temperature at 232 
the die-end of the barrel was required to reduce die swell. The addition of 10 % talc to the 233 
formulation was critical as it improved the flow properties of the powder, ensuring consistent 234 
feeding of the powder into the extruder. When 10 % TEC was added to HPMC-AS-LF the Tg 235 
lowered from 122.8 °C to 97.5 and 91.1 °C after the 1st and 2nd heating cycle respectively. This 236 
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formulation, containing 15 % naproxen, yielded an extrudate with a smooth appearance and 237 
without die swell when processed at 150 °C. The addition of 10 % TEC to HPMCP-HP-50 as 238 
enteric polymer reduced Tg from 142.1 °C to 126.6 and 95.7 °C after the 1st and 2nd heating 239 
cycle, respectively. The 15 % drug-loaded formulation yielded extrudates that were 240 
processable at 145 °C, but had an irregular surface.  241 
At a 15 % naproxen content hot-melt extrusion of all polymer formulations resulted in clear 242 
extrudates with the entire drug content molecularly dispersed in the polymer matrix. A higher 243 
drug load (30 %) resulted in opaque formulations with a significant degree of crystallinity. 244 
However, the extrusion temperature was critical to the physicochemical state of the drug in the 245 
extrudates as nearly the entire naproxen content was molecularly dispersed in the polymer 246 
matrices when processed at a higher temperature (Table 1), e.g. HPMC-AS-LF mixtures with 247 
30 % drug processed at 100 and 120 °C contained 29.0 and 2.6 % crystalline drug, 248 
respectively. This was also reflected in the X-ray diffractogram of the Eudragit® L100-55 249 
extrudates processed at different extrusion temperatures (Fig. 1). Interestingly the 250 
hypromellose-based polymers containing a higher naproxen content could be extruded at a 251 
lower temperature, even when they contained a significant crystalline drug fraction. This can 252 
be linked to the plasticizing effect of naproxen on these polymers: thermal processing of 253 
mixtures with a higher drug content induced more interaction between drug and polymer in the 254 
extrusion barrel. Hence, a lower extrusion temperature could be employed, without risking too 255 
high torque values. This plasticizing effect of naproxen was even more evident for a HPMC-256 
AS-LF formulation containing 50 % naproxen which could be processed without plasticizer at 257 
an extrusion temperature of 120/120/120/110/110/100/100 °C from feed opening to die-end, 258 
despite its high percentage of crystalline drug. 259 
The in-vitro naproxen release profiles of the different polymer formulations containing 10 260 
% TEC as a plasticizer and loaded with 15 % naproxen are shown in Fig. 2. For all formulations 261 
naproxen release in 0.1 N HCl was prevented for 2 h. In pH 6.8 buffer HPMCP-HP-50 matrices 262 
showed a faster release rate compared to HPMC-AS-LF and Eudragit® L100-55 formulations. 263 
Although the process temperature did affect the API’s physicochemical state for the 30 % 264 
12 
 
naproxen formulations, it did not have a significant effect on the release profiles. The enteric 265 
protection of naproxen during a 2 h period was not impaired in formulations containing 30 and 266 
50 % drug. However, naproxen release in pH 6.8 buffer was determined by drug concentration: 267 
after 2 h HPMC-AS-LF matrices containing 30 and 50 % naproxen released 58 and 81 % of 268 
their drug content, respectively (Fig. 3). Drug release form the core matrix was diffusion and 269 
erosion controlled as it was observed that the core slowly eroded during dissolution testing. 270 
A stability study was performed on the transparent extrudates containing 30 % naproxen 271 
and 10 % TEC. Independent of the matrix polymer, naproxen completely recrystallized after 272 
two weeks storage at 40 °C / 75 %RH, while XRD analysis detected no recrystallization over 273 
a 6 month period in a hypromellose matrix stored at 25 °C / 60 %RH. For the 50 % naproxen 274 
formulation in HPMC-AS-LF the physicochemical state nor the dissolution profiles of the drug 275 
had changed after 6 months storage at the different storage conditions (data not shown).  276 
To identify intermolecular interactions between naproxen and polymer (Eudragit® L100-55, 277 
HPMC-AS-LF), Fourier-transform infrared (FT-IR) spectra were collected of transparent 278 
extrudates, containing 30 % drug and plasticized with 10 % TEC, immediately after 279 
manufacturing and after 2 weeks storage at 40 °C / 75 %RH in open condition (i.e. after 280 
recrystallization of the drug). From the FT-IR spectra of the Eudragit® L100-55 formulation 281 
shown in Fig. 4 and Fig. 5 it is suggested that naproxen is mainly molecularly dispersed in the 282 
formulation immediately after processing, since some of the peaks characteristic for naproxen 283 
completely disappeared, e.g. peaks at 1347 cm-1 (rocking of OH of the carboxyl group (Balci, 284 
2014)) and 642 cm-1 (wagging of OH of the carboxyl group (Balci, 2014)), while others 285 
broadened, e.g. peaks at 1416 cm-1 (in-plane bending of CH of the naphthalene ring (Balci, 286 
2014)) and 1628 cm-1 (bond stretching of the naphthalene ring (Balci, 2014)), confirming the 287 
loss of crystalline material (1.3 %). After storage for 2 weeks at 40 °C / 75 %RH the visual 288 
recrystallization in the extrudate was confirmed by the appearance of characteristic naproxen 289 
peaks in the FT-IR spectra (Fig. 5). The changing ratio between the peaks at 1727 cm-1 and 290 
1686 cm-1 (attributed to non-hydrogen and hydrogen bonded –C=O stretching of the crystal 291 
structure (Paudel and Van den Mooter, 2012)) before and after storage implied that the amount 292 
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of hydrogen bonds formed during processing between the drug and the matrix decreased over 293 
time (Fig. 6). While the interaction between drug and polymer is maximal immediately after 294 
processing, the reduction of the peak at 1686 cm-1 after storage clearly indicated that the 295 
amount of hydrogen bonds decreased. The peak shifts observed in the extrudates for the 296 
naproxen peaks at 1227 cm-1 (stretching of CO of the methoxy group (Balci, 2014)) and 1603 297 
cm-1 (bond stretching of the naphthalene ring (Balci, 2014)) are another indication of the 298 
hydrogen bond interaction between drug and matrix (Fig. 4). Also the HPMC-AS-LF 299 
formulations showed a partial recrystallization over time. The characteristic naproxen peaks 300 
were more pronounced in the FT-IR spectra of the extrudates after storage. Moreover after 301 
storage the characteristic naproxen peaks in the FT-IR spectra of the extrudate were not 302 
different from those of pure naproxen (Fig. 7). Also at 1727 and 1686 cm-1 (Fig. 8) the FT-IR 303 
spectrum of the stored extrudate has the same profile as pure drug. This indicated that there 304 
is no permanent interaction between HPMC-AS-LF and naproxen. 305 
3.2. Coat formulation  306 
Formulation of esomeprazole magnesium presents a challenge since degradation of the 307 
drug can occur due to a high process temperature and in acidic environment (Razzaq et al., 308 
2012). When formulating esomeprazole magnesium in the enteric polymers Eudragit® L100-309 
55, HPMC-AS-LF and HPMCP-HP-50 complete degradation of the drug occurred, most likely 310 
due to the presence of acidic groups in the polymers. Therefore esomeprazole magnesium 311 
was formulated in an immediate release polymer, separated from the naproxen-containing 312 
enteric layer. A similar approach was used in a commercially available combination product of 313 
naproxen and esomeprazole magnesium (Vimovo®) which is formulated as an enteric-coated 314 
naproxen tablet with a non-enteric-coated esomeprazole magnesium layer on top (both layers 315 
are physically separated via a barrier coat). The immediate release polymers tested were PEO 316 
100K, Kollidon®12 PF, Klucel® EF and Methocel® E3. While extrusion of the PEO 100K 317 
formulation was feasible at a process temperature of 100 °C, the other polymers required a 318 
processing temperature of 130 °C, even with the addition of a plasticizer, and as a result more 319 
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esomeprazole magnesium degradation occurred: only 40 to 75 % of the drug content was 320 
recovered after extrusion, vs. 94 % drug recovery in the PEO 100K formulation. As drug 321 
release from the PEO 100K polymer was limited to 70 % after 45 min, PEG 4K was added to 322 
the mixtures: complete drug release was observed after 45 min in combination with smooth 323 
processing (lower torque) for a 2 % esomeprazole magnesium loaded PEO 100K : PEG 4K (1 324 
: 1) formulation (Fig. 9). The coat layer rapidly and completely dissolved during dissolution 325 
testing. 326 
Thermal analysis of the physical mixture and the extruded formulation only revealed a 327 
melting endotherm of PEO 100K and PEG 4K, due to dissolution of the esomeprazole 328 
magnesium crystals in molten polymer. While two distinct melting endotherms were detected 329 
for the physical mixture, only a single endotherm was visible in the extruded sample, indicating 330 
the formation of a single phase system.  331 
3.3. Co-extrudate formulation  332 
After evaluating the naproxen-containing enteric layer and the esomeprazole magnesium-333 
containing immediate release layer separately, co-extrusion of 50 % naproxen in the HPMC-334 
AS-LF core and 2 % esomeprazole magnesium in the PEO 100K : PEG 4K 1:1 coat yielded 335 
an opaque co-extrudate with a smooth surface. However, after cooling of the co-extrudate 336 
discoloration was observed at the interface of core and coat (Fig. 10), and in vitro dissolution 337 
revealed that only 72 % of the esomeprazole content could be recovered, despite the fast and 338 
complete dissolution of the PEO / PEG layer. Since this was not seen when processing the co-339 
extrudate with a placebo HPMC-AS-LF + 10 % TEC core, the discoloration is most probably 340 
due to an interaction between the naproxen fraction at the core surface and esomeprazole 341 
magnesium in the coat, leading to degradation of the acid-labile esomeprazole magnesium. A 342 
possible solution to this problem could be the extrusion of a barrier layer between core and 343 
coat. This technique is already applied for the production of multi-layer films in packaging 344 
applications (Thellen et al., 2009, 2012), but could not be evaluated at this stage as it implies 345 
the use of a third extruder.   346 
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4. CONCLUSION 347 
Hot-melt extrusion was a suitable technique to manufacture an enteric 50 % naproxen- 348 
loaded dosage form. Producing a fixed-dose combination product also containing 349 
esomeprazole magnesium in a separate immediate releasing coat was not an adequate 350 
solution to prevent interaction between both chemically incompatible API’s. Co-extrusion as a 351 
continuous one-step manufacturing process for the production of a fixed-dose combination 352 
product providing enteric release to naproxen and immediate release to esomeprazole only 353 
would be feasible when a third layer of polymer, separating the naproxen loaded enteric 354 
formulation in the core from the coat, would be applied to prevent interaction between both 355 
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Tables  425 
Table 1. Extrusion temperature, degree of crystallinity and extrudate appearance of 15, 30 and 426 
50 % naproxen loaded core extrudates, with different matrices.  427 





(from feed opening to die-end) 
Appearance Degree of 
crystallinity 
Eudragit® L100-55 10 % 15 % 100/100/100/100/120/120/120 clear / 
HPMC-AS-LF 10 % 15 % 150/150/150/150/150/150/150 clear / 
HPMCP-HP-50 10 % 15 % 145/145/145/145/145/145/145 clear / 
Eudragit® L100-55 10 % 30 % 110/110/110/110/125/125/125 clear 1.3 % 
100/100/100/100/110/110/110 opaque 37.3 % 
HPMC-AS-LF 10 % 30 % 120/120/120/120/120/120/120 clear 2.6 % 
100/100/100/100/100/100/100 opaque 29.0 % 
HPMCP-HP-50 10 % 30 % 130/130/130/130/130/130/130 clear 0.7 % 
115/115/115/115/115/115/115 opaque spots 1.5 % 
HPMC-AS-LF / 50 % 120/120/120/110/110/100/100 opaque 70.8 % 
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Table 2. Glass transition temperatures (Tg) of placebo and drug-loaded (15 and 30 %) physical 433 
mixtures measured by MDSC in a 2nd heating cycle.  434 
Formulation Tg (° C) 
 Eudragit®L100-55 + 10%TEC HPMC-AS-LF + 10%TEC HPMCP-HP-50 + 
10%TEC 
100% matrix 90.2 91.1 95.7 
85% matrix + 
15% naproxen 61.4 63.4 59.0 
70% matrix + 
30% naproxen 24.9 24.2 26.9 
 435 
  436 
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Figures  437 
Fig. 1. X-ray diffraction patterns of (from bottom to top): naproxen (A), Eudragit® L100-55 (B), 438 
the formulation containing 30 % naproxen in a 70 % (Eudragit® L100-55 : TEC 9:1) matrix, 439 
processed at, from feed opening to die-end, 110/110/110/110/125/125/125 °C (C) and 440 
100/100/100/100/110/110/110 °C (D). 441 
Fig. 2. In-vitro naproxen release profile of formulations containing 15 % naproxen and an 442 
enteric polymer, plasticized with 10 % TEC: Eudragit® L100-55 (●), HPMC-AS-LF (■), HPMCP-443 
HP-50 (▲). Dissolution in 0.1 N HCl (2 h) and pH 6.8 buffer (10 h) at 37 °C using paddle 444 
dissolution system at 100 rpm (Mean ± SD; n=3). 445 
Fig. 3. In-vitro naproxen release profile of two extruded HPMC-AS-LF formulations with 30 (●) 446 
and 50 (■) % drug load. Dissolution in 0.1 N HCl (2 h) and pH 6.8 buffer (10 h) at 37 °C using 447 
paddle dissolution system at 100 rpm (Mean ± SD; n=3).  448 
Fig. 4. ATR FT-IR spectra of naproxen (blue), Eudragit® L100-55 (green), physical mixture of 449 
Eudragit® L100-55 plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the 450 
extrudate of the same formulation immediately after processing (yellow). 451 
Fig. 5. ATR FT-IR spectra of naproxen (blue), physical mixture of Eudragit® L100-55 452 
plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the extrudate of the 453 
same formulation immediately after processing (yellow) and after storage for 2 weeks at 40 °C 454 
/ 75 %RH (grey). 455 
Fig. 6. ATR FT-IR spectra of naproxen (blue), physical mixture of Eudragit® L100-55 456 
plasticized with 10 % TEC and a drug load of 30 % naproxen (red), the extrudate of the same 457 
formulation immediately after processing (yellow) and after storage for 2 weeks at 40 °C / 75 458 
%RH (grey). 459 
Fig. 7. ATR FT-IR spectra of naproxen (blue), HPMC-AS-LF (green), the physical mixture of 460 
HPMC-AS-LF plasticized with 10 % TEC and a drug load of 30% naproxen (red), the extrudate 461 
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of the same formulation immediately after processing (yellow) and after storage for 2 weeks at 462 
40 °C / 75 %RH (grey). 463 
Fig. 8. ATR FT-IR spectra of naproxen (blue), physical mixture of HPMC-AS-LF plasticized 464 
with 10 % TEC and a drug load of 30 % naproxen (red), the extrudate of the same formulation 465 
immediately after processing (yellow) and after storage for 2 weeks at 40 °C / 75 %RH (grey). 466 
Fig. 9. In-vitro esomeprazole Mg release from the coat extrudate containing 2 % esomeprazole 467 
Mg formulated in PEO 100K : PEG 4K 1 : 1 (▲) and pure esomeprazole Mg powder (●). 468 
Dissolution in demineralized water for 2 h at 37 °C using paddle dissolution system at 100 rpm 469 
(Mean ± SD; n=3). 470 
Fig. 10. Top view and detail of separated core and coat layer from final co-extrudate, 471 
containing 50 % naproxen in the HPMC-AS-LF core and 2 % esomeprazole magnesium in 472 
the PEO 100K : PEG 4K 1:1 coat, showing a discoloration at the core surface.   473 
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Fig. 1. X-ray diffraction patterns of (from bottom to top): naproxen (A), Eudragit® L100-55 (B), 475 
the formulation containing 30 % naproxen in a 70 % (Eudragit® L100-55 : TEC 9:1) matrix, 476 
processed at, from feed opening to die-end, 110/110/110/110/125/125/125 °C (C) and 477 
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HP-50 (▲). Dissolution in 0.1 N HCl (2 h) and pH 6.8 buffer (10 h) at 37 °C using paddle 489 
dissolution system at 100 rpm (Mean ± SD; n=3). 490 

























  492 
26 
 
Fig. 3. In-vitro naproxen release profile of two extruded HPMC-AS-LF formulations with 30 (●) 493 
and 50 (■) % drug load. Dissolution in 0.1 N HCl (2 h) and pH 6.8 buffer (10 h) at 37 °C using 494 
paddle dissolution system at 100 rpm (Mean ± SD; n=3).  495 
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Fig. 4. ATR FT-IR spectra of naproxen (blue), Eudragit® L100-55 (green), physical mixture of 498 
Eudragit® L100-55 plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the 499 
extrudate of the same formulation immediately after processing (yellow). 500 
 501 
  502 
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Fig. 5. ATR FT-IR spectra of naproxen (blue), physical mixture of Eudragit® L100-55 503 
plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the extrudate of the 504 
same formulation immediately after processing (yellow) and after storage for 2 weeks at 40 °C 505 
/ 75 %RH (grey). 506 
 507 
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Fig. 6. ATR FT-IR spectra of naproxen (blue), physical mixture of Eudragit® L100-55 509 
plasticized with 10 % TEC and a drug load of 30 % naproxen (red), the extrudate of the same 510 
formulation immediately after processing (yellow) and after storage for 2 weeks at 40 °C / 75 511 
%RH (grey). 512 
 513 
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Fig. 7. ATR FT-IR spectra of naproxen (blue), HPMC-AS-LF (green), the physical mixture of 515 
HPMC-AS-LF plasticized with 10 % TEC and a drug load of 30% naproxen (red), the extrudate 516 
of the same formulation immediately after processing (yellow) and after storage for 2 weeks at 517 
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Fig. 8. ATR FT-IR spectra of naproxen (blue), physical mixture of HPMC-AS-LF plasticized 523 
with 10 % TEC and a drug load of 30 % naproxen (red), the extrudate of the same formulation 524 
immediately after processing (yellow) and after storage for 2 weeks at 40 °C / 75 %RH (grey). 525 
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Fig. 9. In-vitro esomeprazole Mg release from the coat extrudate containing 2 % esomeprazole 527 
Mg formulated in PEO 100K : PEG 4K 1 : 1 (▲) and pure esomeprazole Mg powder (●). 528 
Dissolution in demineralized water for 2 h at 37 °C using paddle dissolution system at 100 rpm 529 
(Mean ± SD; n=3). 530 
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Fig. 10. Top view and detail of separated core and coat layer from final co-extrudate, 533 
containing 50 % naproxen in the HPMC-AS-LF core and 2 % esomeprazole magnesium in the 534 
PEO 100K : PEG 4K 1:1 coat, showing a discoloration at the core surface.  535 
 536 
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